Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 852194, 14 pages
http://dx.doi.org/10.1155/2015/852194
Research Article

Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B

College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA

Received 13 August 2015; Accepted 8 September 2015

Academic Editor: Vincenzo De Feo

Copyright © 2015 Najla O. Zarmouh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Abdullah, I. Basak, K. S. Patil, G. Alves, J. P. Larsen, and S. G. Møller, “Parkinson's disease and age: the obvious but largely unexplored link,” Experimental Gerontology, vol. 68, pp. 33–38, 2015. View at Publisher · View at Google Scholar
  2. M. W. Jann, “Advanced strategies for treatment of Parkinson's disease: the role of early treatment,” The American journal of managed care, vol. 17, supplement 12, pp. S315–S321, 2011. View at Google Scholar · View at Scopus
  3. A. Sturza, M. S. Leisegang, A. Babelova et al., “Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta,” Hypertension, vol. 62, no. 1, pp. 140–146, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Xiao, F. Lv, W. Xu, L. Zhang, P. Jing, and X. Cao, “Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk,” Toxicology, vol. 290, no. 2-3, pp. 286–294, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Maruyama, T. Yamamoto, K. Kitani, M. C. Carrillo, M. Youdim, and M. Naoi, “Mechanism underlying anti-apoptotic activity of a (−)deprenyl-related propargylamine, rasagiline,” Mechanisms of Ageing and Development, vol. 116, no. 2-3, pp. 181–191, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. B. E. Yoon, J. Woo, Y. E. Chun et al., “Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition,” The Journal of Physiology, vol. 592, no. 22, pp. 4951–4968, 2014. View at Publisher · View at Google Scholar
  7. S. Jo, O. Yarishkin, Y. J. Hwang et al., “GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease,” Nature Medicine, vol. 20, no. 8, pp. 886–896, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Weinreb, T. Amit, O. Bar-Am, Y. Sagi, S. Mandel, and M. B. Youdim, “Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety,” Journal of Neural Transmission. Supplementum, vol. 70, pp. 457–465, 2006. View at Google Scholar
  9. M. B. H. Youdim, D. Edmondson, and K. F. Tipton, “The therapeutic potential of monoamine oxidase inhibitors,” Nature Reviews Neuroscience, vol. 7, no. 4, pp. 295–309, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Dias, E. Junn, and M. M. Mouradian, “The role of oxidative stress in parkinson's disease,” Journal of Parkinson's Disease, vol. 3, no. 4, pp. 461–491, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. A. W. Bach, N. C. Lan, D. L. Johnson et al., “cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 13, pp. 4934–4938, 1988. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Friedman, P. Arosio, D. Finazzi, D. Koziorowski, and J. Galazka-Friedman, “Ferritin as an important player in neurodegeneration,” Parkinsonism and Related Disorders, vol. 17, no. 6, pp. 423–430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. B. H. Youdim and P. F. Riederer, “Monoamine oxidase A and B inhibitors in Parkinson's disease,” in Handbook of Clinical Neurology, C. K. William and M. Eldad, Eds., pp. 93–120, Elsevier, 2007. View at Google Scholar
  14. J. P. M. Finberg and K. Gillman, “Selective inhibitors of monoamine oxidase type B and the ‘cheese effect’,” International Review of Neurobiology, vol. 100, pp. 169–190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. I. Shulman, N. Herrmann, and S. E. Walker, “Current place of monoamine oxidase inhibitors in the treatment of depression,” CNS Drugs, vol. 27, no. 10, pp. 789–797, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. N. J. Kolla, S. Attard, G. Craig, N. Blackwood, and S. Hodgins, “Monoamine oxidase A alleles in violent offenders with antisocial personality disorder: high activity associated with proactive aggression,” Criminal Behaviour and Mental Health, vol. 24, no. 5, pp. 368–372, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Culpepper, “Reducing the burden of difficult-to-treat major depressive disorder: revisiting monoamine oxidase inhibitor therapy,” The Primary Care Companion for CNS Disorders, vol. 15, no. 5, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. S. M. Stahl and A. Felker, “Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants,” CNS Spectrums, vol. 13, no. 10, pp. 855–870, 2008. View at Google Scholar · View at Scopus
  19. R. J. Rojas, D. E. Edmondson, T. Almos, R. Scott, and M. E. Massari, “Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques,” Bioorganic and Medicinal Chemistry, vol. 234, no. 4, pp. 770–778, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Gerlach, P. Riederer, and M. B. H. Youdim, “The molecular pharmacology of L-deprenyl,” European Journal of Pharmacology: Molecular Pharmacology, vol. 226, no. 2, pp. 97–108, 1992. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Hubálek, C. Binda, M. Li et al., “Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues,” Journal of Medicinal Chemistry, vol. 47, no. 7, pp. 1760–1766, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Binda, F. Hubálek, M. Li et al., “Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class,” Journal of Medicinal Chemistry, vol. 47, no. 7, pp. 1767–1774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. L. H. A. Prins, J. P. Petzer, and S. F. Malan, “Inhibition of monoamine oxidase by indole and benzofuran derivatives,” European Journal of Medicinal Chemistry, vol. 45, no. 10, pp. 4458–4466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. K. F. Tipton, S. Boyce, J. O'Sullivan, G. P. Davey, and J. Healy, “Monoamine oxidases: certainties and uncertainties,” Current Medicinal Chemistry, vol. 11, no. 15, pp. 1965–1982, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. J. S. Fowler, N. D. Volkow, J. Logan et al., “Slow recovery of human brain MAO B after L-deprenyl (selegeline) withdrawal,” Synapse, vol. 18, no. 2, pp. 86–93, 1994. View at Publisher · View at Google Scholar · View at Scopus
  26. E. D. Deeks, “Safinamide: first global approval,” Drugs, vol. 75, no. 6, pp. 705–711, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. P. S. Khushboo, V. M. Jadhav, V. J. Kadam, and N. S. Sathe, “Psoralea corylifolia Linn.-‘Kushtanashini’,” Pharmacognosy Reviews, vol. 4, no. 7, pp. 69–76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Mazzio, S. Deiab, K. Park, and K. F. A. Soliman, “High throughput screening to identify natural human monoamine oxidase B inhibitors,” Phytotherapy Research, vol. 27, no. 6, pp. 818–828, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Chopra, A. K. Dhingra, and K. L. Dhar, “Psoralea corylifolia L. (Buguchi)—folklore to modern evidence: review,” Fitoterapia, vol. 90, pp. 44–56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. M. RafiqKhan and R. Ranjini, “Preliminary phytochemical screening of seeds of Psoralea corylifolia,” International Research Journal of Pharmacy, vol. 41, pp. 129–130, 2013. View at Google Scholar
  31. H. Mao, H. Wang, S. Ma et al., “Bidirectional regulation of bakuchiol, an estrogenic-like compound, on catecholamine secretion,” Toxicology and Applied Pharmacology, vol. 274, no. 1, pp. 180–189, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. L.-T. Yi, Y.-C. Li, Y. Pan et al., “Antidepressant-like effects of psoralidin isolated from the seeds of Psoralea Corylifolia in the forced swimming test in mice,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 2, pp. 510–519, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. A.-R. Im, S.-W. Chae, G. J. Zhang, and M.-Y. Lee, “Neuroprotective effects of Psoralea corylifolia Linn seed extracts on mitochondrial dysfunction induced by 3-nitropropionic acid,” BMC Complementary and Alternative Medicine, vol. 14, article 370, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. C. N. Backhouse, C. L. Delporte, R. E. Negrete et al., “Active constituents isolated from Psoralea glandulosa L. with antiinflammatory and antipyretic activities,” Journal of Ethnopharmacology, vol. 78, no. 1, pp. 27–31, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Xiao, G. Li, L. Chen et al., “Isolation of antioxidants from Psoralea corylifolia fruits using high-speed counter-current chromatography guided by thin layer chromatography-antioxidant autographic assay,” Journal of Chromatography A, vol. 1217, no. 34, pp. 5470–5476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. P. Valley, W. Zhou, E. M. Hawkins et al., “A bioluminescent assay for monoamine oxidase activity,” Analytical Biochemistry, vol. 359, no. 2, pp. 238–246, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. R.-M. Lin, D.-W. Wang, Z.-L. Xiong, Y. Xu, and F.-M. Li, “HPLC determination of two flavonoid compounds in Psoralea corylifolia,” Zhongguo Zhong Yao Za Zhi, vol. 27, no. 9, pp. 670–671, 2002. View at Google Scholar · View at Scopus
  38. R. M. Kandadai, S. A. Jabeen, M. A. Kanikannan, and R. Borgohain, “Safinamide for the treatment of Parkinson's disease,” Expert Review of Clinical Pharmacology, vol. 7, no. 6, pp. 747–759, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. M. McGann, “FRED and HYBRID docking performance on standardized datasets,” Journal of Computer-Aided Molecular Design, vol. 26, no. 8, pp. 897–906, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. P. C. D. Hawkins, A. G. Skillman, G. L. Warren, B. A. Ellingson, and M. T. Stahl, “Conformer generation with OMEGA: algorithm and validation using high quality structures from the protein databank and cambridge structural database,” Journal of Chemical Information and Modeling, vol. 50, no. 4, pp. 572–584, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. F. P. Turkmenoglu, İ. Baysal, S. Ciftci-Yabanoglu et al., “Flavonoids from Sideritis species: human monoamine oxidase (hMAO) inhibitory activities, molecular docking studies and crystal structure of xanthomicrol,” Molecules, vol. 20, no. 5, pp. 7454–7473, 2015. View at Publisher · View at Google Scholar
  42. N. D. Chaurasiya, M. A. Ibrahim, I. Muhammad, L. A. Walker, and B. L. Tekwani, “Monoamine oxidase inhibitory constituents of propolis: kinetics and mechanism of inhibition of recombinant human MAO-A and MAO-B,” Molecules, vol. 19, no. 11, pp. 18936–18952, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. R. N. Gacche and N. A. Dhole, “Profile of aldose reductase inhibition, anti-cataract and free radical scavenging activity of selected medicinal plants: an attempt to standardize the botanicals for amelioration of diabetes complications,” Food and Chemical Toxicology, vol. 49, no. 8, pp. 1806–1813, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Park, D. H. Kim, H.-N. Ahn, Y. S. Song, Y. J. Lee, and J.-H. Ryu, “Activation of estrogen receptor by bavachin from Psoralea corylifolia,” Biomolecules and Therapeutics, vol. 20, no. 2, pp. 183–188, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Dreiseitel, G. Korte, P. Schreier et al., “Berry anthocyanins and their aglycons inhibit monoamine oxidases A and B,” Pharmacological Research, vol. 59, no. 5, pp. 306–311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. X. Chen, Y. Yang, and Y. Zhang, “Isobavachalcone and bavachinin from Psoraleae Fructus modulate Aβ42 aggregation process through different mechanisms in vitro,” FEBS Letters, vol. 587, no. 18, pp. 2930–2935, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. S.-H. Lim, T.-Y. Ha, J. Ahn, and S. Kim, “Estrogenic activities of Psoralea corylifolia L. seed extracts and main constituents,” Phytomedicine, vol. 18, no. 5, pp. 425–430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Novaroli, A. Daina, E. Favre et al., “Impact of species-dependent differences on screening, design, and development of MAO B inhibitors,” Journal of Medicinal Chemistry, vol. 49, no. 21, pp. 6264–6272, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Chimenti, R. Fioravanti, A. Bolasco et al., “A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors,” Bioorganic and Medicinal Chemistry, vol. 18, no. 3, pp. 1273–1279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. L. J. Legoabe, A. Petzer, and J. P. Petzer, “Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives,” European Journal of Medicinal Chemistry, vol. 49, pp. 343–353, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. L. J. Legoabe, A. Petzer, and J. P. Petzer, “Selected C7-substituted chromone derivatives as monoamine oxidase inhibitors,” Bioorganic Chemistry, vol. 45, pp. 1–11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. K. K. Anand, M. L. Sharma, B. Singh, and B. J. Ghatak, “Antiinflamatory, antipyretic & analgesic properties of bavachinin-a flavanone isolated from seeds of Psoralea corylifolia Linn. (Babchi),” Indian Journal of Experimental Biology, vol. 1611, pp. 1216–1217, 1978. View at Google Scholar
  53. S. W. Lee, B. R. Yun, M. H. Kim et al., “Phenolic compounds isolated from Psoralea corylifolia inhibit il-6-induced STAT3 activation,” Planta Medica, vol. 78, no. 9, pp. 903–906, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. X. Chen, Y. Shen, Q. Liang et al., “Effect of Bavachinin and its derivatives on T cell differentiation,” International Immunopharmacology, vol. 19, no. 2, pp. 399–404, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. C.-C. Cheng, Y.-H. Chen, W.-L. Chang et al., “Phytoestrogen bavachin mediates anti-inflammation targeting IκB kinase-IκBα-NF-κB signaling pathway in chondrocytes in vitro,” European Journal of Pharmacology, vol. 636, no. 1–3, pp. 181–188, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. S.-Y. Yu, L.-J. Zuo, F. Wang et al., “Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study,” BMC Neurology, vol. 14, article 113, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Thomas, “Monoamine oxidase-B inhibitors in the treatment of Alzheimers disease,” Neurobiology of Aging, vol. 21, no. 2, pp. 343–348, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Du, L. Feng, Z. Yang et al., “Separation and peroxisome proliferator-activated receptor-γ agonist activity evaluation of synthetic racemic bavachinin enantiomers,” Bioorganic & Medicinal Chemistry Letters, vol. 25, no. 12, pp. 2579–2583, 2015. View at Publisher · View at Google Scholar
  59. H. L. Martin, R. B. Mounsey, S. Mustafa, K. Sathe, and P. Teismann, “Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease,” Experimental Neurology, vol. 235, no. 2, pp. 528–538, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. A. R. Carta, “PPAR-gamma: therapeutic prospects in Parkinson's disease,” Current Drug Targets, vol. 14, no. 7, pp. 743–751, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. X. Dong, Y. Wang, T. Liu et al., “Flavonoids as vasorelaxant agents: synthesis, biological evaluation and quantitative structure activities relationship (QSAR) studies,” Molecules, vol. 16, no. 10, pp. 8257–8272, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Liu, K.-N. Liu, Y.-B. Wen, H.-W. Zhang, Y.-X. Lu, and Z. Yin, “Development of a fully automated on-line solid phase extraction and high-performance liquid chromatography with diode array detection method for the pharmacokinetic evaluation of bavachinin: a study on absolute bioavailability and dose proportionality,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 893-894, pp. 21–28, 2012. View at Publisher · View at Google Scholar · View at Scopus